Phaseline

Targets › PRMT5

PRMT5 (Protein arginine N-methyltransferase 5): drug programs, companies and trials

13 programs from 11 companies in 31 trials: 25 Phase 1, 6 Phase 2; Oncology, Other, Gastroenterology; next expected readout Nov 2026.

Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA. Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core…. (UniProt, O14744)

Open in Phaseline: the race on PRMT5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbNavlimetostat (BMS-986504)
Selective, MTA-cooperative PRMT5 inhibitor
PRMT5, MTAPPhase 2Solid Tumors; Pancreatic Ductal Adenocarcinoma; Healthy Participants; Healthy Female Participants …Nov 2026
Amgenanvumetostat
PRMT5 inhibitor in MTAP-deleted tumors
PRMT5Phase 2MTAP-deleted NSCLC; Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers; Advanced MTAP-null Solid Tumors; Thoracic TumorsNov 2026
Bristol-Myers SquibbBMS-986504 (MRTX1719)
Selective MTA-cooperative inhibitor of PRMT5
MTAP, PRMT5Phase 2Carcinoma, Non-Small-Cell Lung; Metastatic Non-small Cell Lung Cancer With MTAP Deletion; Advanced Solid Tumors; Advanced Solid Tumors With Homozygous MTAP Deletion …Jan 2027
Tango TherapeuticsTNG456
selective PRMT5 inhibitor
PRMT5Phase 1Non Small Cell Lung CancerMar 2027
Servier Bio-InnovationTNG462
PRMT5 inhibitor
PRMT5Phase 1MTAP-deleted Solid TumorsMay 2027
Tango TherapeuticsTNG462
Selective PRMT5 inhibitor
PRMT5Phase 1Locally Advanced Solid Tumor; PDACJun 2027
Jiangsu Simcere PharmaceuticalSCR-6920 capsule
PRMT5 inhibitor
PRMT5Phase 1Solid TumorOct 2027
PharmaEnginePEP08
MTA-cooperative PRMT5 inhibitor
PRMT5Phase 1Advanced Solid TumorDec 2027
Jubilant Therapeutics IndiaJBI-778
Selective PRMT5 inhibitor
PRMT5Phase 1NSCLC Patients With EGFR Activating MutationMar 2028
IDEAYA BiosciencesIDE892
PRMT5 inhibitor
PRMT5Phase 1NSCLC AdenocarcinomaApr 2028
AstraZenecaAZD3470
PRMT5 inhibitor
PRMT5Phase 1Advanced Solid Tumors That Are MTAP Deficient; LymphomaDec 2028
BayerBAY 3713372
PRMT5 inhibitor
PRMT5Phase 1MTAP-deleted Solid TumorsJun 2029
Northwestern UniversityBMS-986504
PRMT5 inhibitor
PRMT5Phase 1Metastatic Biliary Tract CarcinomaDec 2030

Conditions

MTAP-deleted Solid Tumors (2) Solid Tumors (1) Pancreatic Ductal Adenocarcinoma (1) Healthy Participants (1) Healthy Female Participants (1) Healthy Female Adults (1) Phase 2 Study (1) Non-Small Cell Lung Cancer (1) Advanced Cancer (1) NSCLC Adenocarcinoma (1) MTAP-deleted NSCLC (1) Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers (1)

Modalities

small molecule (11), mixed (2)

Companies

Bristol-Myers Squibb (2) Tango Therapeutics (2) Bayer (1) IDEAYA Biosciences (1) Amgen (1) Jubilant Therapeutics India (1) Jiangsu Simcere Pharmaceutical (1) Northwestern University (1) AstraZeneca (1) PharmaEngine (1) Servier Bio-Innovation (1)

Related targets

MTAP (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.